225 related articles for article (PubMed ID: 37999140)
1. Clinical and Molecular Features of Morpheaform Basal Cell Carcinoma: A Systematic Review.
Conte S; Ghezelbash S; Nallanathan B; Lefrançois P
Curr Oncol; 2023 Nov; 30(11):9906-9928. PubMed ID: 37999140
[TBL] [Abstract][Full Text] [Related]
2. Morpheaform Basal Cell Carcinomas With Areas of Predominantly Single-Cell Pattern of Infiltration: Diagnostic Utility of p63 and Cytokeratin.
East E; Fullen DR; Arps D; Patel RM; Palanisamy N; Carskadon S; Harms PW
Am J Dermatopathol; 2016 Oct; 38(10):744-50. PubMed ID: 27043336
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of cytokeratin 15, TDAG51, cytokeratin 20 and androgen receptor in sclerosing adnexal neoplasms and variants of basal cell carcinoma.
Evangelista MT; North JP
J Cutan Pathol; 2015 Nov; 42(11):824-31. PubMed ID: 26016446
[TBL] [Abstract][Full Text] [Related]
4. Can smoking and/or occupational UV exposure have any role in the development of the morpheaform basal cell carcinoma? A critical role for peritumoral mast cells.
Erbagci Z; Erkiliç S
Int J Dermatol; 2002 May; 41(5):275-8. PubMed ID: 12100702
[TBL] [Abstract][Full Text] [Related]
5. The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers.
Sellheyer K; Nelson P; Kutzner H; Patel RM
J Cutan Pathol; 2013 Apr; 40(4):363-70. PubMed ID: 23398472
[TBL] [Abstract][Full Text] [Related]
6. Morpheaform basal cell carcinoma in African Americans.
Nadiminti U; Rakkhit T; Washington C
Dermatol Surg; 2004 Dec; 30(12 Pt 2):1550-2. PubMed ID: 15606838
[TBL] [Abstract][Full Text] [Related]
7. [Not Available].
Cribier B
Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS3-VS11. PubMed ID: 30477681
[TBL] [Abstract][Full Text] [Related]
8. Dermoscopic Clues of Histopathologically Aggressive Basal Cell Carcinoma Subtypes.
Camela E; Ilut Anca P; Lallas K; Papageorgiou C; Manoli SM; Gkentsidi T; Eftychidou P; Liopyris K; Sgouros D; Apalla Z; Lallas A
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837550
[No Abstract] [Full Text] [Related]
9. Basal cell carcinoma: clinical and pathological features.
Di Stefani A; Chimenti S
G Ital Dermatol Venereol; 2015 Aug; 150(4):385-91. PubMed ID: 26099353
[TBL] [Abstract][Full Text] [Related]
10. Basal cell carcinoma: a dermatopathological and molecular biological update.
Saldanha G; Fletcher A; Slater DN
Br J Dermatol; 2003 Feb; 148(2):195-202. PubMed ID: 12588368
[TBL] [Abstract][Full Text] [Related]
11. Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: differentiation by immunohistochemistry and determining the need for Mohs micrographic surgery.
Merritt BG; Snow SN; Longley BJ
Cutis; 2010 May; 85(5):254-8. PubMed ID: 20540416
[TBL] [Abstract][Full Text] [Related]
12. Histologically Agressive Basal Cell Carcinoma With Particular Emphasis On Galeal Infiltration Of The Scalp.
Requena C; Serra-Guillén C; Sanmartín O
Actas Dermosifiliogr; 2022 Jun; 113(6):575-582. PubMed ID: 35339267
[TBL] [Abstract][Full Text] [Related]
13. Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults.
Ferrante di Ruffano L; Dinnes J; Chuchu N; Bayliss SE; Takwoingi Y; Davenport C; Matin RN; O'Sullivan C; Roskell D; Deeks JJ; Williams HC;
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD013187. PubMed ID: 30521689
[TBL] [Abstract][Full Text] [Related]
14. Destruction of the orbit and globe by recurrence of basal cell carcinoma.
Chew R
Optometry; 2007 Jul; 78(7):344-51. PubMed ID: 17601572
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of cytokeratin 17 immunostaining in morpheaform basal cell carcinoma and for facilitating the detection of tumor cells at the surgical margins.
Anderson-Dockter H; Clark T; Iwamoto S; Lu M; Fiore D; Falanga JK; Falanga V
Dermatol Surg; 2012 Aug; 38(8):1357-66. PubMed ID: 22691048
[TBL] [Abstract][Full Text] [Related]
16. alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation.
Marsh D; Dickinson S; Neill GW; Marshall JF; Hart IR; Thomas GJ
Cancer Res; 2008 May; 68(9):3295-303. PubMed ID: 18451156
[TBL] [Abstract][Full Text] [Related]
17. Basal cell carcinoma in Singapore: a prospective study on epidemiology and clinicopathological characteristics with a secondary comparative analysis between Singaporean Chinese and Caucasian patients.
Tan ES; Ee M; Shen L; Chua H; Chan YH; Tan SH
Australas J Dermatol; 2015 Aug; 56(3):175-9. PubMed ID: 25179179
[TBL] [Abstract][Full Text] [Related]
18. Ln-γ 2 chain of laminin-332 is a useful marker in differentiating between benign and malignant sclerosing adnexal neoplasms.
Koga K; Anan T; Fukumoto T; Fujimoto M; Nabeshima K
Histopathology; 2020 Jan; 76(2):318-324. PubMed ID: 31429981
[TBL] [Abstract][Full Text] [Related]
19. Recurrence rates of aggressive histologic types of basal cell carcinoma after treatment with electrodesiccation and curettage alone.
Blixt E; Nelsen D; Stratman E
Dermatol Surg; 2013 May; 39(5):719-25. PubMed ID: 23379543
[TBL] [Abstract][Full Text] [Related]
20. Basal cell carcinoma of the axilla: review of the world literature.
Cohen PR
Am J Clin Dermatol; 2014 Apr; 15(2):95-100. PubMed ID: 24567258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
